Teva Stripped of Generic Celebrex Exclusivity

Source: Jewish Business News

Dec 18, 2014

A U.S. appeals court has overturned the FDA decision that granted Teva Pharmaceuticals 180-day exclusivity for the generic version of Pfizer's arthritis treatment, Celebrex.

This will delay Teva's generic launch until June 2015, and give Teva's rivals, including Mylan, Watson and Lupin, the the opportunity to also launch generic versions of Celebrex.

While Teva was the first to file its Celebrex generic with the FDA, the court ruled that the patent for Celebrex had expired and consequently, Teva was not entitled to the exclusivity.

Read the Jewish Business News article

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments